Biologic characteristics of an immunosuppressive factor derived from a human lung cancer cell line

Abstract

A 549, a human lung cancer cell line, spontaneously produces a tumor-derived immunosuppressive factor (TDSF) which inhibited PHA-stimulated T lymphocyte proliferation via a noncytotoxic mechanism. The inhibition increased in a dose-dependent pattern. The factor also markedly suppressed production of interleukin (IL-2) by PHA-stimulated lymphocytes and IL 2-dependent proliferation of activated lymphocytes. The fact that TDSF possessed very potent inhibitive action on IL-2 is especially noteworthy if we consider the use of IL-2 as immunotherapeutic agent. The synthesis of the factor was inhibited by mitomycin C, actinomycin D and cycloheximide, indicating that the factor is a genic product of A 549 cells. The factor is chemically a protein with a molecular weight greater than 150 KD and sensitve to extremes of pH, heating to 60 °C and trypsin treatment.

Keywords

A 549 culture supernatant / tumor-derived immunosuppressive factor / interleukin 2

References

[1] GlasgowAH, et al. . Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer. N Engl J Med, 1974, 291: 1263-7

[2] ReyA, et al. . Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells. Immunol Lett, 1983, 6: 175-8

[3] OhSK, et al. . Nonspecific immunosuppressive factors in malignant ascites: further characterization and possible relationship to erythrocyce in in receptors of human peripher T cells. J Immunol, 1981, 27: 2300-7

[4] T 1984; 4(2): 69–73.

[5] WerkmeisterJ, et al. . Detection of an inhibitor of cell division in cultures of tumor cells with immunosuppressive activity in vitro. Clin Exp Immunol, 1980, 40: 168-77

[6] EbertEC, et al. . Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol, 1987, 138: 2161-8

[7] FontanaA, et al. . Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol, 1984, 132: 1837-44